Back to top
more

Integer Holdings (ITGR)

(Real Time Quote from BATS)

$129.32 USD

129.32
28,381

+3.15 (2.50%)

Updated Sep 13, 2024 12:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Integer Holdings (ITGR) Q3 Earnings Top Estimates, FY23 View Up

by Zacks Equity Research

Integer Holdings' (ITGR) third-quarter results reflect robust Medical Sales, along with strength in the majority of the product lines.

Integer (ITGR) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

Integer (ITGR) delivered earnings and revenue surprises of 20.95% and 8.71%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

MedTech Stocks to Watch for Earnings on Oct 26: WST, DXCM & More

by Debanjana Dey

MedTech companies' Q3 results are likely to reflect strength in customer demand. Let's see how WST, DXCM, MMSI and ITGR are placed ahead of their earnings releases.

Revvity's (RVTY) New Tie-Up to Boost NGS Research Workflow

by Zacks Equity Research

Revvity's (RVTY) latest partnership is likely to address the workflow-related challenges faced by labs and democratize genomic sequencing.

3 Reasons to Add Integer Holdings (ITGR) Stock to Your Portfolio

by Zacks Equity Research

Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.

QuidelOrtho (QDEL) Reports Solid Preliminary Q3 Revenues

by Zacks Equity Research

QuidelOrtho's (QDEL) revenue growth in the third quarter is likely to have been boosted by continued strength in its non-respiratory product sales.

Merit Medical's (MMSI) New Launch to Expand Its Product Suite

by Zacks Equity Research

Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly improve patient outcomes.

ITGR vs. EW: Which Stock Is the Better Value Option?

by Zacks Equity Research

ITGR vs. EW: Which Stock Is the Better Value Option?

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark

by Zacks Equity Research

Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery.

3 Reasons to Add Surmodics (SRDX) Stock to Your Portfolio

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio

by Zacks Equity Research

Inogen's (INGN) potential in the POC space and a strong product portfolio raise optimism about the stock.

Veradigm (MDRX)-FDB Vela to Enhance Pharmacy Connectivity

by Zacks Equity Research

Veradigm's (MDRX) latest progress with FDB Vela is likely to offer prescribers and patients greater choice and cost transparency.

Three Reasons to Add PacBio (PACB) Stock to Your Portfolio

by Zacks Equity Research

PacBio's (PACB) product development activities raise optimism about the stock.

OPKO Health (OPK) Gets BARDA Contract to Combat Antibody Threats

by Zacks Equity Research

OPKO Health's (OPK) latest awarded funding is likely to enable the development of novel multispecific antibodies against viral infectious disease threats.

3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

by Zacks Equity Research

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Veradigm (MDRX) Advances Tie-Up to Enhance Care Delivery

by Zacks Equity Research

Veradigm's (MDRX) new phase of strategic investment is likely to drive innovation and close the evidence gap in behavioral health.

AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

AngioDynamics (ANGO) delivered earnings and revenue surprises of 14.29% and 1.32%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?

Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans

by Zacks Equity Research

Accuray's (ARAY) latest offering is likely to improve radiation treatment.

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on business recovery and expansion in emerging markets.

Veradigm's (MDRX) New Tie-Up to Boost Patients' Health Outcomes

by Zacks Equity Research

Veradigm's (MDRX) latest partnership is likely to promote value-based care initiatives for healthcare providers and the patients they serve.

Here's Why You Should Retain Ecolab (ECL) Stock for Now

by Zacks Equity Research

Ecolab's (ECL) strength in its business raises optimism about the stock.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors are optimistic about Medtronic (MDT) on strong global expansion.

3 Reasons to Hold Catalent (CTLT) Stock in Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) product and service launches and a slew of strategic deals raise optimism about the stock.

Here's Why You Should Invest in Penumbra (PEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about Penumbra (PEN), driven by growth in vascular and neuro businesses.